Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.
Mikhael J, Belhadj-Merzoug K, Hulin C, Vincent L, Moreau P, Gasparetto C, Pour L, Spicka I, Vij R, Zonder J, Atanackovic D, Gabrail N, Martin TG, Perrot A, Bensfia S, Weng Q, Brillac C, Semiond D, Macé S, Corzo KP, Leleu X. Mikhael J, et al. Among authors: semiond d. Blood Cancer J. 2021 May 12;11(5):89. doi: 10.1038/s41408-021-00478-4. Blood Cancer J. 2021. PMID: 33980831 Free PMC article. Clinical Trial. No abstract available.
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.
Dimopoulos MA, Leleu X, Moreau P, Richardson PG, Liberati AM, Harrison SJ, Miles Prince H, Ocio EM, Assadourian S, Campana F, Malinge L, Sémiond D, van de Velde H, Yong K. Dimopoulos MA, et al. Among authors: semiond d. Leukemia. 2021 Feb;35(2):562-572. doi: 10.1038/s41375-020-0868-z. Epub 2020 May 23. Leukemia. 2021. PMID: 32444867 Free PMC article. Clinical Trial.
Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.
Rachedi F, Koiwai K, Gaudel-Dedieu N, Sebastien B, Thai HT, Brillac C, Fau JB, Nguyen L, van de Velde H, Veyrat-Follet C, Semiond D. Rachedi F, et al. Among authors: semiond d. CPT Pharmacometrics Syst Pharmacol. 2022 Jun;11(6):766-777. doi: 10.1002/psp4.12789. Epub 2022 Apr 17. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 35355430 Free PMC article. Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 36164138
PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma.
Koiwai K, El-Cheikh R, Thai HT, Brillac C, Fau JB, Veyrat-Follet C, Risse ML, van de Velde H, Semiond D, Nguyen L. Koiwai K, et al. Among authors: semiond d. CPT Pharmacometrics Syst Pharmacol. 2021 Aug;10(8):928-940. doi: 10.1002/psp4.12666. Epub 2021 Jul 8. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 34185964 Free PMC article.
28 results